Aduro Biotech, which is developing an immunotherapy for pancreatic cancer, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.
2014 immuno-oncology biotech IPOs have traded well, including Kite Pharma (KITE; +287%), Immune Design (IMDZ; +114%) and Juno Therapeutics (JUNO; +108%).
The Berkeley, CA-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol ADRO.
Help employers find you! Check out all the jobs and post your resume.
